Correct usage and dosage of macitentan (Aoposu) and medication recommendations for patients at different stages

Macitentan (Macitentan) is an oral dual endothelin receptor antagonist (ERA), mainly used to treat pulmonary arterial hypertension (PAH), including idiopathic, congenital heart disease-related and connective tissue disease-related PAH. By inhibiting the activity of endothelin receptors ETA and ETB, it reduces pulmonary vasoconstriction and inhibits vascular remodeling, thereby reducing pulmonary artery pressure and improving right heart function. Rational use of macitentan can significantly improve patients' exercise tolerance and quality of life.

The clinical standard dosage is 10 mg orally once daily. It can be taken in the morning or evening without meals. For well-tolerated adult patients, this dose can usually maintain stable blood concentrations and ensure efficacy. During the initial treatment phase, standard doses should be started while monitoring liver function, hemoglobin, and blood pressure to ensure patient safety. For patients with mildly impaired liver function, extending the reexamination interval may be considered, but generally no dosage adjustment is required; patients with severe liver function impairment should use it with caution or be disabled.

For patients at different stages ofPAH, the medication strategies are different. Mild to moderate patients usually respond to single drug treatment, and the efficacy can be evaluated through the 6 minute walk test and NT-proBNP levels; moderate to severe patients can Combined with other PAH-targeting drugs (such as phosphodiesterase 5 inhibitors or prostacyclin receptor agonists) according to the condition to improve efficacy and delay disease progression. Patients with acute cardiac insufficiency or hypotension need to assess their hemodynamic status before taking medication and start or adjust the dosage carefully.

Safety matters need to be paid attention to during medication, including regular monitoring of liver function, hemoglobin and electrocardiogram to prevent the occurrence of anemia or abnormal liver function; at the same time, avoid combining with potent CYP3A4 inhibitors or inducers to avoid affecting drug metabolism and blood concentration. Pregnant and nursing women are prohibited from using macitentan. By strictly following the dosage regimen, combined with patient condition and staged assessment, macitentan can achieve safe and effective long-term treatment in PAH patients at different stages.

Reference materials:https://www.drugs.com/